Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a...
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial
About this item
Full title
Author / Creator
Publisher
London: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Summary Background Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. We aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis. Methods The SELECT-AXIS 2 non-radiographic axial spondyloarthritis study was a multicentre, randomised, double-blin...
Alternative Titles
Full title
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2697091450
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2697091450
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(22)01212-0
